Lv1
28 积分 2024-10-01 加入
An in vitro T cell Dysfunction/Exhaustion Assay System that is partially reversible by pembrolizumab
3个月前
已完结
Enhancing the activation of T cells through anti‐CD3/CD28 magnetic beads by adjusting the antibody ratio
4个月前
已完结
Establishment of Cell-Based Assay System for Evaluating Cytotoxic Activity Modulated by the Blockade of PD-1 and PD-L1 Interactions with a Therapeutic Antibody
4个月前
已完结
Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms – Report of an international collaborative study
4个月前
已完结
In Vitro Complement-Dependent Cytotoxicity and Antibody-Dependent Cellular Cytotoxicity by the Anti-TNF Agents Adalimumab, Etanercept, Infliximab, and Certolizumab Pegol (CDP870)
5个月前
已关闭
The state of the art in secondary pharmacology and its impact on the safety of new medicines
5个月前
已完结
Important Considerations for ELISpot Validation
6个月前
已完结
皖公网安备34019202002308
